Para depositar en Docta Complutense, identifícate con tu correo @ucm.es en el SSO institucional. Haz clic en el desplegable de INICIO DE SESIÓN situado en la parte superior derecha de la pantalla. Introduce tu correo electrónico y tu contraseña de la UCM y haz clic en el botón MI CUENTA UCM, no autenticación con contraseña.

Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies

dc.contributor.authorJemni Damer , Nahla
dc.contributor.authorGuedan Duran , Atocha
dc.contributor.authorFuentes Andion , María
dc.contributor.authorSerrano Bengoechea , Nora
dc.contributor.authorAlfageme Lopez, Nuria
dc.contributor.authorArmada Maresca, Felix
dc.contributor.authorGuinea , Gustavo V.
dc.contributor.authorPerez Rigueiro , José
dc.contributor.authorRojo Vázquez, Francisco Antonio
dc.contributor.authorGonzalez Nieto, Daniel
dc.contributor.authorKaplan, David L.
dc.contributor.authorPanetsos Petrova, Fivos
dc.date.accessioned2024-01-11T09:16:37Z
dc.date.available2024-01-11T09:16:37Z
dc.date.issued2020-12-10
dc.description.abstractAge-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 y.o. people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting on intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, different treatment options have to be considered. Cell therapy is a very promising alternative to drug-based approaches for AMD treatment. Cells delivered to the affected tissue as a suspension have shown poor retention and low survival rate. A solution to these inconveniences has been the encapsulation of these cells on biomaterials, which contrive to their protection, gives them support, and favor their retention of the desired area. We offer a two-papers critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In this second part we review the preclinical and clinical cell-replacement approaches aiming at the development of efficient AMD-therapies, the employed cell types, as well as the cell-encapsulation and cell-implant systems. We discuss their advantages and disadvantages and how they could improve the survival and integration of the implanted cells.
dc.description.departmentDepto. de Biodiversidad, Ecología y Evolución
dc.description.facultyFac. de Óptica y Optometría
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Economía y Competitividad (España)
dc.description.sponsorshipComunidad de Madrid (España)
dc.description.sponsorshipNational Institutes of Health (España)
dc.description.statuspub
dc.identifier.citationJemni-Damer N, Guedan-Duran A, Fuentes-Andion M, Serrano-Bengoechea N, Alfageme-Lopez N, Armada-Maresca F, Guinea GV, Perez-Rigueiro J, Rojo F, Gonzalez-Nieto D, Kaplan DL and Panetsos F (2020) Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies. Front. Bioeng. Biotechnol. 8:588014.
dc.identifier.doi10.3389/fbioe.2020.588014
dc.identifier.essn2296-4185
dc.identifier.officialurlhttps://doi.org/10.3389/fbioe.2020.588014
dc.identifier.urihttps://hdl.handle.net/20.500.14352/92433
dc.issue.numberart.588014
dc.journal.titleFrontiers in Bioengineering and Biotechnology
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.projectIDMAT2016-76847-R
dc.relation.projectIDMAT2016-79832-R
dc.relation.projectIDMAT2015-66666-C3-3-R
dc.relation.projectIDNeurocentro-B2017/BrMD-3760
dc.relation.projectIDIND2018/BrMD-9804
dc.relation.projectIDP41EB002520
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu57.08
dc.subject.keywordretinal pigment epithelium, Bruch’s membrane, photoreceptors, biomaterials, cell therapy, tissue engineering, biotechnology, cell replacement
dc.subject.ucmBiotecnología
dc.subject.unesco3201.09 Oftalmología
dc.titleBiotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number8
dspace.entity.typePublication
relation.isAuthorOfPublication8a17e57c-529b-41e4-827c-1472424182be
relation.isAuthorOfPublication1279018d-18b3-4bb8-b291-d43947d907b2
relation.isAuthorOfPublication.latestForDiscovery8a17e57c-529b-41e4-827c-1472424182be

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
fbioe-08-588014.pdf
Size:
1.76 MB
Format:
Adobe Portable Document Format

Collections